NCT03911453View on ClinicalTrials.gov

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 19, 2019

Primary Completion Date

July 16, 2021

Study Completion Date

July 16, 2021

Conditions
Breast Cancer
Interventions
DRUG

Rucaparib

Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of PD-L1 by Immunohistochemical assay (IHC).

Trial Locations (1)

85724

University of Arizona Cancer Center, Tucson

All Listed Sponsors
lead

University of Arizona

OTHER

NCT03911453 - Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | Biotech Hunter | Biotech Hunter